0.075
-0.01 (-9.64%)
| Previous Close | 0.083 |
| Open | 0.082 |
| Volume | 4,804,237 |
| Avg. Volume (3M) | 2,115,445 |
| Market Cap | 88,790,248 |
| Price / Sales | 704.72 |
| Price / Book | 10.27 |
| 52 Weeks Range | |
| Earnings Date | 18 Aug 2025 - 19 Aug 2025 |
| Profit Margin | -181.62% |
| Operating Margin (TTM) | -49.62% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | 77.00% |
| Current Ratio (MRQ) | 11.24 |
| Operating Cash Flow (TTM) | -6.09 M |
| Levered Free Cash Flow (TTM) | -4.60 M |
| Return on Assets (TTM) | -45.61% |
| Return on Equity (TTM) | -85.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | AROVELLA FPO [ALA] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 2.50 |
|
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 27.34% |
| % Held by Institutions | 5.29% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |